Ringpu Bio-Technology proposes board reshuffle, governance overhaul

Tianjin Ringpu Bio-Technology’s board of directors convened on November 28, 2025, to approve key changes in governance and board composition. The company proposes electing five non-independent directors and three independent directors for the sixth board, with a three-year term commencing upon shareholder approval.

Among the nominated non-independent directors are Mr. Li Shoujun (current chairman), Mr. Xu Lei, Ms. Liu Ailing, Mr. Zhu Xiutong, and Ms. Li Rui. Independent director nominees include Mr. Dong Yichun, Mr. Wang Kai, and Ms. Li Ya. These changes, including the independent director candidates, require registration approval from the Shenzhen Stock Exchange and cumulative voting at the upcoming shareholder meeting.

The board also approved revisions to the company’s Articles of Association, eliminating the supervisory board and transferring its functions to the audit committee. This change necessitates updates to various internal control systems, including the "Shareholder Meeting Rules" and "Board of Directors Meeting Rules." Additionally, three new policies were introduced: "Management System for Directors and Senior Executives Leaving Office," "Management System for Providing External Financial Assistance," and "Management System for Remuneration of Directors and Senior Executives."

All proposed amendments and elections are subject to approval at the Sixth Extraordinary General Meeting of Shareholders, scheduled for December 15, 2025. This meeting will be held via a combination of on-site voting and online proxy. Shareholder registration for this meeting will take place on December 12, 2025.